20:17 , Jul 7, 2017 |  BC Week In Review  |  Company News

NICE recommends Sobi's Xiaflex in FAD

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Xiapex collagenase clostridium histolyticum from Swedish Orphan Biovitrum AB (SSE:SOBI) to treat Dupuytren's disease in adults with a palpable cord who are...
01:38 , Jun 23, 2015 |  BC Extra  |  Company News

Management tracks

Rare disease play Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) named Jayson Dallas chief commercial officer, effective Aug. 3. Dallas was general manager in the U.K. at Roche (SIX:ROG; OTCQX:RHHBY). Hepatic company Intercept Phamaceuticals Inc. (NASDAQ:ICPT) named Juan...
07:00 , Jun 15, 2015 |  BioCentury  |  Finance

Deerfield pays Tribute to Pozen

Deerfield is betting $300 million on the combination of a Canadian cardiovascular specialty pharma with a U.S. biotech that has new management, a late-stage cardio asset and a royalty stream. The firm is backing a...
00:22 , Jun 3, 2015 |  BC Extra  |  Company News

Management tracks

Neurology play Pozen Inc. (NASDAQ:POZN) named Adrian Adams CEO, replacing retiring Chairman, President and CEO John Plachetka. Adams was CEO of Auxilium Pharmaceuticals Inc. , which Endo International plc (NASDAQ:ENDP; TSX:ENL) acquired. Cancer company Ziopharm...
02:04 , Mar 19, 2015 |  BC Extra  |  Company News

Management tracks

Agilent Technologies Inc. (NYSE:A) promoted Mike McMullen from COO to CEO; he will retain his role as president. He succeeds William Sullivan, who will be a company advisor until his retirement on Oct. 31. Trovagene...
01:42 , Mar 12, 2015 |  BC Extra  |  Top Story

Endo the road for Salix

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) gained $10.96 to $168.61 after Endo International plc (NASDAQ:ENDP; TSX:ENL) attempted to outbid Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) with a buyout offer for Salix of $175 per share, or $11.2...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

Xiaflex collagenase clostridium histolyticum regulatory update

The European Commission approved Xiapex collagenase clostridium histolyticum from Swedish Orphan to treat Peyronie’s disease with a palpable plaque and curvature deformity of 30 degrees. The injectable form of collagenase is also approved in the...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Company News

Auxilium, Endo deal

Endo completed its acquisition of Auxilium in a deal valued at $2.6 billion Auxilium Pharmaceuticals Inc. , Chesterbrook, Pa.   Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland   Business: Musculoskeletal, Genitourinary, Endocrine/Metabolic  ...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Financial News

Endo completes private placement of senior notes

Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland   Business: Neurology, Genitourinary   Date completed: 2015-01-21   Type: Private placement of senior notes   Raised: $1.2 billion   Note: The unsecured, unsubordinated notes bear 6% interest...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

Xiaflex collagenase clostridium histolyticum regulatory update

EMA’s CHMP recommended expanding the label of Xiapex collagenase clostridium histolyticum from Swedish Orphan to include the treatment of Peyronie’s disease with a palpable plaque and curvature deformity of >=30 degrees. The injectable form of...